RxDoctor Payments Data

Tricia Koch

Nurse Practitioner · Neenah, WINPI 1538263223

Payments from drug & device makers

$1,081in general payments, 2019–2025

Across 33 payments — averaging $32.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$200
  • AbbVie$197
  • Sumitomo Pharma America, Inc.$177
  • Teleflex LLC$119
  • Ferring Pharmaceuticals Inc.$115
  • Astellas Pharma US Inc$69
  • plus $204 from 8 others

What the payments were for

  • Food & beverage$1,06799%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,081 in reported general payments places this provider in the 90th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$133,068
Medicare patients
539
Services billed
3,526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron385$266,919
GemtesaVibegron57$50,987
ElmironPentosan Polysulfate Sodium16$34,272
Tamsulosin Hcl985$16,235
Fosfomycin Tromethamine18$9,961
Solifenacin Succinate265$9,706
Mirabegron ErMirabegron21$8,751
RenacidinCitric Ac/Gluconolact/Mag Carb22$4,362
Finasteride309$3,862
Testosterone13$3,540
NitrofurantoinNitrofurantoin Macrocrystal143$3,106
Potassium Citrate ErPotassium Citrate18$3,049
Oxybutynin Chloride ErOxybutynin Chloride114$2,970
Fesoterodine Fumarate ErFesoterodine Fumarate45$2,889
Estradiol44$2,858

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$69$266,919385 claims
Sumitomo Pharma America, Inc.Gemtesa$177$50,98757 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in Neenah

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →